These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 23490404

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
    Vergilis-Kalner IJ.
    J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B, Dunphy C, Lee R, Lee D, Sheth S, Marks L, Kaplan SA, Te AE.
    Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
    Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children.
    Blackburn SC, Jones C, Bedoya S, Steinbrecher HA, Malone PS, Griffin SJ.
    J Pediatr Urol; 2013 Dec; 9(6 Pt A):750-3. PubMed ID: 23036518
    [Abstract] [Full Text] [Related]

  • 14. Chapter 6: Practical aspects of administration of onabotulinumtoxinA.
    Rovner E.
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S32-7. PubMed ID: 25042141
    [Abstract] [Full Text] [Related]

  • 15. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
    Peyronnet B, Castel-Lacanal E, Manunta A, Roumiguié M, Marque P, Rischmann P, Gamé X.
    Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder.
    Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P.
    Neurourol Urodyn; 2011 Apr; 30(4):556-62. PubMed ID: 21351127
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes.
    Okamura K, Nojiri Y, Ameda K, Namima T, Suzuki M, Inoue K, Ogawa T, Gotoh M, Homma Y.
    Int J Urol; 2011 Jun; 18(6):483-7. PubMed ID: 21488978
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.